METHODS
Records of 128 (81 male, 47 female) adult patients with
high-grade glioma treated with radiotherapy between January
2003-December 2007 were retrospectively reviewed. Of
these cohorts, 98% had pathologically confirmed subtypes and
among those, 46% (n=58) underwent total exision, 34% (n=43)
underwent subtotal exision and 14% (n=18) biopsied. Median
age was 46 for grade 3 tumors and was 53 for grade 4. KPS
was ≤70 for 40%. Sixteen GBM patients received concurrent,
14 received adjuvant TMZ.
RESULTS
For a median folllow-up of 12 (1-80) months, 1 and 3-year
overall survival for the entire group were 44.5% and 15.3%
respectively. Median survival was 21 months for grade 3 and 9
months for grade 4. Age ≤50 (p=0.002), biopsy versus total and
subtotal resection (p<0.001), preoperative KPS >70 (p<0.001)
were statistically significant good prognosticators. Concurrent
and/or adjuvant use of temozolamide had positive impact on
survival of grade 4-GBM patients (p=0.02 and p<0.001).
CONCLUSION
In our series, KPS, resection type and age were found to be the
most significant prognostic factors. Despite the use in small
number of GBM patients, concurrent and/or adjuvant TMZ,
positively affected survival.
Keywords: Brain tumor; radiotherapy; prognostic factors
